Why Vera Therapeutics Stock Zoomed Higher Today
One of the happiest moments an investor in the biotech sector can have is when one of his or her companies reports a regulatory submission for a promising product. Sure enough, investors snapped up shares of Vera Therapeutics (NASDAQ: VERA) on Wednesday, sending them to a nearly 5% gain, on the company's news that it made such a filing.
That morning, Vera announced that its biologics license application (BLA) for its atacicept was accepted for priority review by U.S. healthcare regulator, the Food and Drug Administration (FDA). Atacicept is a drug that targets IgA nephropathy (IgAN), a kidney affliction that's also known as Berger's disease.
Image source: Getty Images.
Source Fool.com
